ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Richard M. Engelman
Daniel T. Engelman
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshida, T.
Right arrow Articles by Das, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshida, T.
Right arrow Articles by Das, D. K.

Ann Thorac Surg 2000;70:895-900
© 2000 The Society of Thoracic Surgeons


Original articles: cardiovascular

Preconditioning of swine heart with monophosphoryl lipid A improves myocardial preservation

Tetsuya Yoshida, MDa, Richard M. Engelman, MDc, Daniel T. Engelman, MDc, John A. Rousou, MDc, Nilanjana Maulik, PhDa, Motoaki Sato, MDa, Gary T. Elliott, PhD, PharmDb, Dipak K. Das, PhDa

a Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut, USA
b RIBI ImmunoChem Research, Inc, Hamilton, Montana, USA
c Department of Surgery, Baystate Medical Center, Springfield, Massachusetts, USA

Address reprint requests to Dr Richard Engelman, Division of Cardiac Surgery, Baystate Medical Center, 759 Chestnut St, Suite 4628, Springfield, MA 01199

Background. Ischemic preconditioning has been proven to be a powerful tool for myocardial protection in the setting of ischemia and reperfusion. A new drug to provide pharmacologic preconditioning, monophosphoryl lipid A (MLA), was administered 24 hours before an acute coronary occlusion in pigs to determine the effect on pharmacologic preconditioning.

Methods. Two studies were completed. In the first, swine were distributed into five groups: group I, control; group II,. aminoguanidine (AMG) (30 mg/kg), a selective inducible nitric oxide synthase (iNOS) blocker; group III, MLA (10 µg/kg); group IV, MLA (35 µg/kg); and group V, MLA and AMG (35 µg/kg and 30 mg/kg, respectively). Twenty-four hours after administration of the MLA, AMG, or both, regional left anterior descending coronary artery ischemia was induced for 15 minutes followed by one hour of global normothermic cardioplegic arrest and three hour reperfusion. Left ventricular function, tissue injury, and percentage of myocardial infarction were measured. Left ventricular myocardium in the left anterior descending coronary artery region was sampled for iNOS messenger RNA (mRNA) during ischemia and reperfusion. In the second study, pigs were sacrificed 0, 4, 6, 8, and 24 hrs after MLA/AMG administration for iNOS mRNA determination in nonischemic myocardium.

Results. Use of MLA significantly improved postischemic ventricular function, and reduced creatinine kinase release and percentage of infarction. Monophosphoryl lipid A induced expression of iNOS mRNA in nonischemic myocardium within four hours of administration which returned to base line by 24 hours. Normothermic regional ischemia then induced expression of iNOS mRNA, which returned to base line during reperfusion. Aminoguanidine completely abolished both MLA-induced and ischemia-induced iNOS mRNA and blocked the beneficial effects of MLA.

Conclusions. Use of MLA can provide myocardial preservation through enhanced expression of iNOS mRNA.




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. D. Lasley, B. J. Keith, G. Kristo, Y. Yoshimura, and R. M. Mentzer Jr.
Delayed adenosine A1 receptor preconditioning in rat myocardium is MAPK dependent but iNOS independent
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H785 - H791.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. B. Haitsma, D. Merkus, J. Vermeulen, P. D. Verdouw, and D. J. Duncker
Nitric oxide production is maintained in exercising swine with chronic left ventricular dysfunction
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2198 - H2209.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. B. Haitsma, D. Merkus, J. Vermeulen, P. D. Verdouw, and D. J. Duncker
Nitric oxide production is maintained in exercising swine with chronic left ventricular dysfunction
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2198 - H2209.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.